Clinical Study of WT2725 in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 17, 2017

Study Completion Date

May 17, 2017

Conditions
Cancer
Interventions
BIOLOGICAL

WT2725

WT2725 injection Study drug will be administered every 1-4 weeks

Trial Locations (6)

17033

Penn State Milton S. Hershey Medical Center, Hershey

60637

The University of Chicago Medical Center, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

The University of Texas, MD Anderson Cancer Center, Houston

85719

The University of Arizona Cancer Center - North Campus, Tucson

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Sumitomo Pharma Co., Ltd.

INDUSTRY

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01621542 - Clinical Study of WT2725 in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter